Dongsung Pharmaceutical Co Ltd

Dongsung Pharmaceutical has a market price of 973 KRW and a market cap of 23.75 billion KRW, with a price-to-book ratio of 1.02 and a price-to-tangible-book ratio of 1.02. The company's enterprise value to revenue is 1.01, and its enterprise value to EBITDA is -5.10, indicating a negative EBITDA. The company's debt-to-equity ratio is 2.74, and its current ratio is 0.69, suggesting liquidity constraints. The company's return on equity is -1.10, and its return on assets is -0.15, both significantly below the industry median for pharmaceutical and personal products firms. These metrics indicate poor profitability and asset utilization relative to its peers. The operating margin is negative, and the net margin is also negative, reflecting a challenging operating environment. Dongsung Pharmaceutical's revenue is concentrated in domestic and overseas markets, with no disclosed segment breakdown. The company's exposure to geographic markets is not specified, but its revenue concentration suggests potential vulnerability to regional economic shifts. The lack of segment-level data limits the ability to assess diversification. The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the outlook. The operating cash flow is negative, and the free cash flow is also negative, indicating a lack of cash generation. The capital expenditure is modest, but the company is not investing significantly in growth. The risk assessment indicates medium liquidity risk and low dilution risk. The company has a negative net cash position after subtracting total debt, which could constrain its ability to meet short-term obligations. The dilution risk is low, but the company's financial position remains fragile. Recent events and filings do not provide specific details on the company's strategic direction or operational changes. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.